Efficiency of postoperative statin treatment for preventing new-onset postoperative atrial fibrillation in patients undergoing isolated coronary artery bypass grafting: A prospective randomized study

Anatol J Cardiol. 2015 Jun;15(6):491-5. doi: 10.5152/akd.2014.5531. Epub 2014 Jun 3.

Abstract

Objective: Recent studies have demonstrated that preoperative statin therapy reduces the incidence of postoperative atrial fibrillation (AF). The objective of this study was to assess the efficacy of statin therapy started in the early postoperative period for the prevention from new-onset AF after isolated coronary artery bypass grafting (CABG).

Methods: This prospective and randomized study consisted of 60 consecutive patients who underwent elective isolated CABG. Patients were divided into two groups to examine the influence of statins: those with postoperative statin therapy (statin group, n=30) and those without it (non-statin group, n=30). Patient data were collected and analyzed prospectively. In the statin group, each extubated patient was given 40 mg of atorvastatin per day, starting from an average of 6 hours after the operation.

Results: The overall incidence of postoperative AF was 30%. Postoperative AF occurred in 5 patients (16.7%) in the statin group. This was significantly lower compared with 13 patients (43.3%) in the non-statin group (p=0.049). According to the multivariate analysis, postoperative atorvastatin reduced the risk of postoperative AF by 49% [odds ratio (OR) 0.512, 95% confidence interval (CI) 0.005 to 0.517, p=0.012]. Also, age was an independent predictor of postoperative AF (OR 1.299, 95% CI 1.115 to 1.514, p=0.001).

Conclusion: Postoperative statin therapy seems to reduce new-onset AF after isolated CABG in our study.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Atorvastatin / administration & dosage
  • Atorvastatin / therapeutic use*
  • Atrial Fibrillation / prevention & control*
  • Coronary Artery Bypass*
  • Echocardiography
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypertrophy, Left Ventricular / diagnostic imaging
  • Middle Aged
  • Postmenopause
  • Postoperative Complications / prevention & control*
  • Prospective Studies
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Atorvastatin